Axsome’s late-stage study of experimental depression drug misses main trial goal
March 31, 2020Manufacturing and Production Depressive Disorder, MDD, depression, migraine
Axsome Therapeutics reported on Monday that its Phase 3 study of its experimental depression drug missed its main trial goal. …
Johnson & Johnson selects lead COVID-19 vaccine candidate and targets September Phase I study
March 31, 2020Manufacturing and Production . Johnson & Johnson, Johnson & Johnson, Vaccine, coronavirus, coronavirus vaccine
Johnson & Johnson announced that it has selected a candidate for a COVID-19 vaccine from potential constructs it has been …
Bayer’s Nubeqa combo approved in Europe for non-metastatic castration-resistant prostate cancer
March 31, 2020Manufacturing and Production, Research and Development Bayer, Cancer, Europe, Nubeqa, prostate cancer
The European Commission has given the green light to Bayer’s non-steroidal androgen receptor inhibitor Nubeqa (darolutamide), jointly developed with Orion, …
UK social distancing measures making a difference to the spread of COVID-19, government says
March 31, 2020Manufacturing and Production British Coronavirus, COVID-`9, coronavirus, coronavirus uk
Social distancing measures are slowing down the spread of coronavirus and keeping pressure off the NHS, according to the UK’s …
EUSA Pharma and Ergomed partner to investigate IL-6 targeting in COVID-19 patients with serious respiratory complications
March 31, 2020Manufacturing and Production, Research and Development COVID-19, Eusa Pharma, coronavirus, ergomed, pharma
Oncology and rare disease firm EUSA Pharma is aiding in the global fight against the novel coronavirus with the launch …
People or profit: What is the best system to regulate drug prices?
March 30, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Conor Kavanagh investigates the role state healthcare institutions play in negotiating drug prices, and what steps can be taken for …
FDA immunotherapy first with the approval of AZ’s Imfinzi in first-line extensive-stage small cell lung cancer
March 30, 2020Sales and Marketing AstraZeneca, Cancer, FDA, Imfinzi, lung cancer, pharma
AstraZeneca has seized FDA approval for its immune checkpoint inhibitor Imfinzi (durvalumab) in the first-line treatment of extensive-stage small cell …
EMA gives market authorisation application to epilepsy treatment from Arvelle Therapeutics
March 30, 2020Sales and Marketing EMA, EMA approvals, approvals, epilepsy
The European Medicines Agency (EMA) has accepted a marketing authorisation application (MAA) for a cenobamate adjunctive treatment of focal-onset seizures …
Sanofi agrees a second partnership to develop a COVID-19 vaccine
March 30, 2020Sales and Marketing Vaccine, china coronavirus, coronavirus, coronavirus vaccine
Sanofi has partnered with Translate Bio to develop a novel messenger RNA (mRNA) vaccine for COVID-19 while they are also …
WHO launches “historic” multinational study to investigate most promising COVID-19 therapies
March 30, 2020Research and Development, Sales and Marketing COVID-19, Gilead, coronavirus, pharma, remdesivir
The World Health Organization continues to push forward in the global fight against the novel coronavirus, and has announced the …
Hydroxychloroquine given to 1,100 patients with COVID-19 in New York
March 30, 2020Sales and Marketing COVID-19, New York, china coronavirus, coronavirus
The malaria drug hydroxychloroquine is being administered to 1,100 patients in New York, which is fast becoming the new epicenter …
Immunron Chief Executive Officer Gary Jacob resigns amidst coronavirus cost-cutting
March 27, 2020Manufacturing and Production
The Chief Executive Officer of Immuron, Gary S. Jacob, has resigned as CEO and as a member of the Board …
FDA invokes emergency powers to authorise 30-minute, handheld COVID-19 test
March 27, 2020Medical Communications, Sales and Marketing COVID-19, FDA, Mesa Biotech, US, coronavirus
The FDA invoked Emergency Use Authorization powers to approve a rapid, handheld testing kit for COVID-19 coronavirus cases just days …
US now leads world in COVID-19 cases as report warns it could face 80,000 deaths in four months
March 27, 2020Medical Communications, Research and Development
The US now leads the world in total number of COVID-19 cases with more than 85,500 positives, ahead of China’s …
Top Ten most popular articles on Pharmafile.com this week
March 27, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, coronavirus
The COVID-19 global pandemic continues to dominate the news cycle. The first clinical trial using danoprevir (Ganovo) in treating COVID-19 …
British Prime Minister Boris Johnson tests positive for coronavirus
March 27, 2020Medical Communications COVID-19, Coroanvirus
British Prime Minister Boris Johnson has tested positive for coronavirus, developing mild symptoms over the last 24 hours which included …
Teva donates millions of hydroxychloroquine sulfate tablets, touted by Trump as coronavirus treatment
March 27, 2020Medical Communications Trump, coronavirus
Teva pharmaceuticals have said they will provide ten million doses of its anti-malaria drug hydroxychloroquine, which President Trump has been …
COVID-19 may significantly hurt the drug supply chains of the biggest pharmaceutical companies
March 27, 2020Medical Communications COVID-19, Coroanvirus, Wuhan Coronavirus, china coronavirus
The increasing spread of the COVID-19 coronavirus pandemic threatens the drug supply lines of the biggest pharmaceutical companies, including AstraZeneca, …
AbbVie won’t defend its patent for Kaletra so it can be made available for coronavirus treatment
March 26, 2020Business Services COVID-19, Ebola Drug, Wuhan Coronavirus, china coronavirus, coronavirus
AbbVie has announce it will not defend its patent to its HIV therapy Kaletra (lopinavir) so it can be made …
FDA approves BMS’ Zeposia in relapsing multiple sclerosis, but COVID-19 will delay its market entry
March 26, 2020Sales and Marketing Bristol-Myers Squibb, COVID-19, Zeposia, coronavirus, multiple sclerosis, pharma
Bristol-Myers Squibb has secured approval with the FDA for Zeposia (ozanimod) 0.92mg in relapsing forms of multiple sclerosis (RMS), but …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
